AJ303

AJ303 is a novel compound under development for the treatment of idiopathic pulmonary fibrosis (IPF). It decreased IPF-related inflammatory cytokines, such as IL-6, MCP1, and GM-CSF in vitro, that delays the progression of pulmonary fibrosis in bleomycin-induced pulmonary injury model in mice.

AJ303 has a favorable plasma to pulmonary ratio of tissue distribution after oral administration. Its potential efficacy in treating patients with IPF will be investigated clinically in 2021.

Current Pipeline

  • 60% 60%
  • 40% 40%
  • 30% 30%
  • 15% 15%
  • 10% 10%

Contact

We look forward to further discussions with you.
Please fill out the form, and we will get right back to you.

+886-02-2365-5677

info@ajpharm.com

B405, No. 18, Siyuan St., Zhongzheng Dist., Taipei City 100, Taiwan (R.O.C.)

13 + 11 =